335 related articles for article (PubMed ID: 26138686)
1. MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice.
Wu Y; Heinrichs J; Bastian D; Fu J; Nguyen H; Schutt S; Liu Y; Jin J; Liu C; Li QJ; Xia C; Yu XZ
Blood; 2015 Sep; 126(11):1314-23. PubMed ID: 26138686
[TBL] [Abstract][Full Text] [Related]
2. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice.
Yang YG; Sergio JJ; Pearson DA; Szot GL; Shimizu A; Sykes M
Blood; 1997 Dec; 90(11):4651-60. PubMed ID: 9373279
[TBL] [Abstract][Full Text] [Related]
4. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
Johnson BD; Becker EE; Truitt RL
Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
[TBL] [Abstract][Full Text] [Related]
5. Promoting regulation via the inhibition of DNAM-1 after transplantation.
Koyama M; Kuns RD; Olver SD; Lineburg KE; Lor M; Teal BE; Raffelt NC; Leveque L; Chan CJ; Robb RJ; Markey KA; Alexander KA; Varelias A; Clouston AD; Smyth MJ; MacDonald KP; Hill GR
Blood; 2013 Apr; 121(17):3511-20. PubMed ID: 23430112
[TBL] [Abstract][Full Text] [Related]
6. Separation of antileukemic effects from graft-versus-host disease in MHC-haploidentical murine bone marrow transplantation: participation of host immune cells.
Satake A; Inoue T; Kubo S; Taniguchi Y; Imado T; Fujioka T; Horiuchi M; Xu Y; Ikegame K; Yoshihara S; Kaida K; Tamaki H; Okada M; Okamura H; Ogawa H
Int J Hematol; 2010 Apr; 91(3):485-97. PubMed ID: 20300982
[TBL] [Abstract][Full Text] [Related]
7. Targeting Sirt-1 controls GVHD by inhibiting T-cell allo-response and promoting Treg stability in mice.
Daenthanasanmak A; Iamsawat S; Chakraborty P; Nguyen HD; Bastian D; Liu C; Mehrotra S; Yu XZ
Blood; 2019 Jan; 133(3):266-279. PubMed ID: 30514750
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects.
Sykes M; Harty MW; Szot GL; Pearson DA
Blood; 1994 May; 83(9):2560-9. PubMed ID: 7909457
[TBL] [Abstract][Full Text] [Related]
9. CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL.
Matte-Martone C; Liu J; Jain D; McNiff J; Shlomchik WD
Blood; 2008 Apr; 111(7):3884-92. PubMed ID: 18223170
[TBL] [Abstract][Full Text] [Related]
10. Allospecific CD4+, Th1/Th2 and CD8+, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL.
Fowler DH; Breglio J; Nagel G; Hirose C; Gress RE
Biol Blood Marrow Transplant; 1996 Oct; 2(3):118-25. PubMed ID: 9199754
[TBL] [Abstract][Full Text] [Related]
11. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
Fowler DH; Gress RE
Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
[TBL] [Abstract][Full Text] [Related]
12. The role of interleukin-12 in preserving the graft-versus-leukemia effect of allogeneic CD8 T cells independently of GVHD.
Yang YG; Sykes M
Leuk Lymphoma; 1999 May; 33(5-6):409-20. PubMed ID: 10342569
[TBL] [Abstract][Full Text] [Related]
13. Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells.
Yang YG; Qi J; Wang MG; Sykes M
Blood; 2002 Jun; 99(11):4207-15. PubMed ID: 12010827
[TBL] [Abstract][Full Text] [Related]
14. Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease.
Zheng H; Matte-Martone C; Li H; Anderson BE; Venketesan S; Sheng Tan H; Jain D; McNiff J; Shlomchik WD
Blood; 2008 Feb; 111(4):2476-84. PubMed ID: 18045967
[TBL] [Abstract][Full Text] [Related]
15. Type I-IFNs control GVHD and GVL responses after transplantation.
Robb RJ; Kreijveld E; Kuns RD; Wilson YA; Olver SD; Don AL; Raffelt NC; De Weerd NA; Lineburg KE; Varelias A; Markey KA; Koyama M; Clouston AD; Hertzog PJ; Macdonald KP; Hill GR
Blood; 2011 Sep; 118(12):3399-409. PubMed ID: 21719602
[TBL] [Abstract][Full Text] [Related]
16. PKCtheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice.
Valenzuela JO; Iclozan C; Hossain MS; Prlic M; Hopewell E; Bronk CC; Wang J; Celis E; Engelman RW; Blazar BR; Bevan MJ; Waller EK; Yu XZ; Beg AA
J Clin Invest; 2009 Dec; 119(12):3774-86. PubMed ID: 19907075
[TBL] [Abstract][Full Text] [Related]
17. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect.
Schmaltz C; Alpdogan O; Horndasch KJ; Muriglan SJ; Kappel BJ; Teshima T; Ferrara JL; Burakoff SJ; van den Brink MR
Blood; 2001 May; 97(9):2886-95. PubMed ID: 11313285
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
[TBL] [Abstract][Full Text] [Related]
19. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity.
Sykes M; Abraham VS; Harty MW; Pearson DA
J Immunol; 1993 Jan; 150(1):197-205. PubMed ID: 8093257
[TBL] [Abstract][Full Text] [Related]
20. Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect.
Clouthier SG; Cooke KR; Teshima T; Lowler KP; Liu C; Connolly K; Ferrara JL
Biol Blood Marrow Transplant; 2003 Sep; 9(9):592-603. PubMed ID: 14506661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
